FDA grants orphan drug designation to glioblastoma treatment
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Iopofosine I 131 may improve survival in pediatric brain cancer
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
Stenoparib may improve survival in hard-to-treat ovarian cancer: Data
The experimental therapy stenoparib (2X-121) may help extend survival in people with hard-to-treat ovarian cancer, according to new clinical trial data announced by the therapy’s…
Iberdomide helps eliminate myeloma cells, trial data show
Iberdomide can help eliminate cancer cells in people with relapsed or refractory multiple myeloma, according to clinical trial results announced by Bristol Myers Squibb…
Project aims to improve AML patients’ access to clinical trials
A new research project aims to make it easier for people with acute myeloid leukemia (AML) to participate in clinical trials. The project is led…
Atebimetinib yields ‘extraordinary’ results in pancreatic cancer trial
An experimental cancer therapy known as atebimetinib is delivering “extraordinary” results for patients with pancreatic cancer. New data from an ongoing Phase 2a clinical…
Voranigo becomes 1st therapy in EU to target IDH-mutated glioma
The European Commission has approved Voranigo (vorasidenib) for certain types of glioma, marking the arrival of a new targeted pill poised to change…
FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
Myeloma treatment combo sees 100% response rate in trial
Combination treatment with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) led to a 100% response rate for 49 people with newly diagnosed…
Cancer network backs Syndax Revuforj for NPM1-mutated AML
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 33 cancer centers, included Revuforj (revumenib) in its clinical practice guidelines for treatment of relapsed or…
